Momentum Healthware Inc.

Momentum Healthware Inc. provides innovative software solutions designed to enhance healthcare delivery and management, focusing on improving patient outcomes through advanced technology. Founded in 1995 in Winnipeg, Canada, Momentum Healthware Inc. specializes in integrated healthcare software solutions.

The company has undergone strategic pivots to align with evolving healthcare demands and was recently acquired by Civica UK Limited in May 2022, enhancing its software offerings. Momentum Healthware has participated in three funding rounds, with the latest being a Venture Debt round amounting to CAD 2. 100 mn led by MMV Capital Partners. Momentum Healthware offers a range of integrated software solutions that aim to improve healthcare delivery.

Their flagship product includes Electronic Health Records (EHR) software, which provides a real-time, unified view of patient information for better clinical decision-making. Additionally, they deliver solutions for care delivery across mental health and community services, clinical pathways management, electronic prescribing, and intelligent scheduling tools, utilized by over 500 healthcare providers across North America, the UK, Australia, New Zealand, and beyond. Momentum Healthware generates revenue primarily through subscription-based software services. Their contracts with healthcare organizations include long-term subscriptions that provide clients with access to software updates and support.

For example, hospitals may subscribe to their EHR system, which encompasses patient management and clinical pathways, contributing to both initial implementation fees and recurring subscription payments. Looking forward, Momentum Healthware aims to leverage recent funding from its acquisition to enhance its software offerings across North America and expand into new markets globally. Specific plans include the development of additional healthcare management products, although release dates are not specified. The acquisition rationale emphasizes increasing their footprint in the North American healthcare market, which is a key strategic focus following the latest deal on May 9, 2022.